AbbVie RINVOQ® Moves Closer to EU Approval for Alopecia Areata
NORTH CHICAGO, Ill., June 29, 2026 AbbVie has announced that the European Medicines Agency’s Committee for Medicinal Products for...
JAK inhibitor
Advertisement
Castle Biosciences Wins 2026 Genomics Innovation Award
FRIENDSWOOD, Texas, May 12, 2026 Castle Biosciences announced that its AdvanceAD-Tx™ gene expression profiling test received the prestigious 2026...
Alkermes Reports Strong Phase 3 LUMRYZ Trial Data
DUBLIN, Ireland, May 12, 2026 Alkermes announced positive topline results from the pivotal REVITALYZ Phase 3 clinical trial evaluating...
Incyte Opzelura Shows Durable Atopic Dermatitis Benefit
WILMINGTON, Del., May 7, 2026 Incyte announced positive 24-week long-term results from the Phase 3 TRuE-AD4 clinical trial evaluating...
Karyopharm SENTRY Trial Advances Myelofibrosis Treatment
Newton, Massachusetts, USA, April 21, 2026 In a major development in hematologic oncology, Karyopharm Therapeutics Inc. has announced that...
Advertisements
LEO Pharma Gains FDA sNDA Acceptance for ANZUPGO
Madison, New Jersey, U.S. | April 15, 2026 LEO Pharma has announced that the U.S. Food and Drug Administration...
Merck Animal Health’s NUMELVI™ Wins FDA Approval
Rahway, New Jersey, USA — February 25, 2026 The U.S. Food and Drug Administration (FDA) has approved NUMELVI™ (atinvicitinib...
AbbVie Raises 2025 Outlook as Skyrizi and Rinvoq Surge
NORTH CHICAGO, Ill., November 2, 2025 — AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical leader, has raised its annual...
FDA Updates RINVOQ® Label for Inflammatory Bowel Disease Use
NORTH CHICAGO, Illinois, October 13, 2025 – AbbVie Inc. (NYSE: ABBV) announced that the U.S. Food and Drug Administration...
Health Canada Approves Bylvay for Cholestatic Pruritus in ALGS
OTTAWA, Canada, September 9, 2025 — Health Canada has granted approval to Bylvay™ (odevixibat) for the treatment of cholestatic...
Advertisement
